Capricor Therapeutics (CAPR) Competitors

Capricor Therapeutics (NASDAQ:CAPR) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Which has better earnings and valuation, CAPR or APGE?

Capricor Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	15.97	-$40.47M	-$1.64	-4.74
Apogee Therapeutics	N/A	N/A	-$182.15M	-$4.13	-9.23

Does the media refer more to CAPR or APGE?

In the previous week, Capricor Therapeutics had 28 more articles in the media than Apogee Therapeutics. MarketBeat recorded 39 mentions for Capricor Therapeutics and 11 mentions for Apogee Therapeutics. Capricor Therapeutics' average media sentiment score of 0.02 beat Apogee Therapeutics' score of -0.03 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Apogee Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate CAPR or APGE?

Capricor Therapeutics currently has a consensus price target of $22.56, indicating a potential upside of 189.92%. Apogee Therapeutics has a consensus price target of $99.00, indicating a potential upside of 159.71%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Capricor Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Apogee Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is CAPR or APGE more profitable?

Apogee Therapeutics has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -181.71%. Apogee Therapeutics' return on equity of -34.65% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	-181.71%	-62.71%	-50.82%
Apogee Therapeutics	N/A	-34.65%	-32.76%

Do institutionals & insiders have more ownership in CAPR or APGE?

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 10.5% of Capricor Therapeutics shares are held by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more volatility and risk, CAPR or APGE?

Capricor Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Summary

Capricor Therapeutics beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.